Clinical Trials · NCT00379015
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Enrollment
- 38
- Start date
- Jan 2006
- Locations
- 5 sites, Japan
- Primary endpoint
- Pathological complete response